At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 329 enrolled
Drug / intervention
Alogliptin +2 moredrug
Likely dose
Alogliptin 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared With Placebo in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Alogliptin and Placebo for Diabetes Mellitus. Completed, enrolled 329 participants across 67 sites in 18 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesArgentina, Australia, Brazil, Chile, Czechia, Dominican Republic, Germany, Guatemala, Hungary, India, Mexico, Netherlands, New Zealand, Peru, Poland, South Africa, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedFeb 2006
Primary CompletionJul 2007
TodayJul 2026
First PostedFeb 3, 2006
Enrollment StartFeb 1, 2006
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 20.4 years ago
Interventions
Alogliptindrug
Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
Alogliptindrug
Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
Placebodrug
Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.